Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Kymera Therapeutics Stock Is Soaring Today

TheMotleyFool 
0 0 09.07.24
Why Kymera Therapeutics Stock Is Soaring Today: https://g.foolcdn.com/editorial/images/782922/scientists-happy.jpg
 

Shares of Kymera Therapeutics (NASDAQ: KYMR) were soaring 18.4% higher as of 11:28 a.m. ET on Tuesday. The big jump came after the clinical-stage biopharmaceutical company announced on Monday that its partner, Sanofi, plans to expand the ongoing phase 2 studies evaluating experimental drug KT-474 in treating two skin conditions: hidradenitis suppurativa and atopic dermatitis.

Sanofi opted to expand the phase 2 studies of KT-474 to accelerate the advancement of the drug into pivotal testing. The French drugmaker's decision came on the heels of a positive preliminary review of KT-474's safety and efficacy data by an Independent Data Review Committee.

Anything that could potentially speed up the timeline for getting a product to market is great news for a clinical-stage biopharma company. Investors are justifiably thrilled with Sanofi's decision to expand phase 2 studies of KT-474.

Continue reading


Source Fool.com

Kt Corporation ADR Stock

€12.20
-1.610%
A loss of -1.610% shows a downward development for Kt Corporation ADR.

Show more
Like: 0
KYMR
Share

Comments

Not a member yet? Sign up for free!